| Cisplatin-based adjuvant chemotherapy in patients with completely resected non–small-cell lung cancer International Adjuvant Lung Cancer Trial Collaborative Group New England Journal of Medicine 350 (4), 351-360, 2004 | 3072 | 2004 |
| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer S Giacchetti, B Perpoint, R Zidani, N Le Bail, R Faggiuolo, C Focan, ... Journal of clinical oncology 18 (1), 136-136, 2000 | 1857 | 2000 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 794 | 2020 |
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? L Arnould, M Gelly, F Penault-Llorca, L Benoit, F Bonnetain, C Migeon, ... British journal of cancer 94 (2), 259-267, 2006 | 717 | 2006 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 700 | 2017 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 587 | 2018 |
| Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, ... Journal of Clinical Oncology 39 (7), 723-733, 2021 | 535 | 2021 |
| Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ... Annals of oncology 29 (4), 959-965, 2018 | 496 | 2018 |
| Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory … S Ladoire, L Arnould, L Apetoh, B Coudert, F Martin, B Chauffert, ... Clinical cancer research 14 (8), 2413-2420, 2008 | 397 | 2008 |
| Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial M Spielmann, H Roché, T Delozier, JL Canon, G Romieu, H Bourgeois, ... Journal of Clinical Oncology 27 (36), 6129-6134, 2009 | 374 | 2009 |
| In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival S Ladoire, G Mignot, S Dabakuyo, L Arnould, L Apetoh, C Rébé, ... The Journal of pathology 224 (3), 389-400, 2011 | 277 | 2011 |
| Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic … S Giacchetti, G Bjarnason, C Garufi, D Genet, S Iacobelli, M Tampellini, ... Journal of clinical oncology 24 (22), 3562-3569, 2006 | 246 | 2006 |
| Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study E Raymond, AA Brandes, C Dittrich, P Fumoleau, B Coudert, ... Journal of Clinical Oncology 26 (28), 4659-4665, 2008 | 245 | 2008 |
| Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer PF Innominato, C Focan, T Gorlia, T Moreau, C Garufi, J Waterhouse, ... Cancer research 69 (11), 4700-4707, 2009 | 231 | 2009 |
| [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy A Berriolo-Riedinger, C Touzery, JM Riedinger, M Toubeau, B Coudert, ... European journal of nuclear medicine and molecular imaging 34, 1915-1924, 2007 | 201 | 2007 |
| Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—trial for the French Study Group … S Culine, A Lortholary, JJ Voigt, R Bugat, C Théodore, F Priou, ... Journal of clinical oncology 21 (18), 3479-3482, 2003 | 184 | 2003 |
| Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients E Limagne, C Richard, M Thibaudin, JD Fumet, C Truntzer, A Lagrange, ... Oncoimmunology 8 (4), e1564505, 2019 | 179 | 2019 |
| Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy S Ladoire, L Arnould, G Mignot, B Coudert, C Rébé, F Chalmin, J Vincent, ... Breast cancer research and treatment 125, 65-72, 2011 | 177 | 2011 |
| Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy JD Fumet, C Richard, F Ledys, Q Klopfenstein, P Joubert, B Routy, ... British journal of cancer 119 (8), 950-960, 2018 | 168 | 2018 |
| Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2–overexpressing stage II or III … BP Coudert, R Largillier, L Arnould, P Chollet, M Campone, D Coeffic, ... Journal of clinical oncology 25 (19), 2678-2684, 2007 | 168 | 2007 |
Pierre FumoleauInstitut CurieVerifisert e-postadresse på curie.fr